Dr. Demidenko received his Ph.D. from Central Institute of Economics & Mathematics, Academy of Sciences, USSR. Since 1992 he works at the Department of Biomedical Data Science, Geisel School of Medicine and Department of Mathematics, Dartmouth College. He is the author of more than 140 peer-reviewed papers and two books in statistics (www.eugened.org). He collaborates with pharmacology and cancer researchers on the regular basis. According to a recently released database by Stanford University, he is among top 2% of World Scientists.

Prof. Sinerik Ayrapetyan has received his PhD in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev during the period of 1966-1970. Currently, he is the Chairholder of UNESCO Chair at Life Sciences International Postgraduate Educational Center, and Coordinator of UNESCO/UNITWIN Interregional Network on Research and Postgraduate Education in Biophysics, Biotechnology and Environmental Health, Yerevan, Armenia. His research has included the study of metabolic regulation of cell function in norm and pathology. He is serving as a Chief Editor for the Journal of “Bioequivalence and Bioavailability”, and me editorial member of several International  journals, He has authored 7 international books and more than 200 research articles. Current research interest is “Intracellular Signaling System in Norm and Pathology”.

Dr. Ranjan is the Professor and Endowed Chair in the College of Veterinary Medicine, Oklahoma State University. Dr. Ranjan earned his veterinary medicine degree from Madras Veterinary College, in Chennai, India. He earned a Ph.D. in Biomedical and Veterinary Sciences from Virginia Tech. Dr. Ranjan then was a Visiting Fellow at the Center for Interventional Oncology, Department of Radiology and Imaging Sciences at the National Institutes of Health (NIH). His research interests are in the application of device directed nanoparticles for solid tumor chemo-immunotherapy. His lab is actively engaged in preclinical and veterinary clinical trials, and has received funding from several federal, state and private sources. Dr. Ranjan has received the NIH Merit, OSU distinguished faculty, regents research, and president’s fellow awards in the recent years. He also serves in the Scientific Advisory Board of Focused Ultrasound Foundation, and several NIH panels.

Dr. Rucha Sane received her B.Pharm. in India and her Ph.D. from University of Cincinnati in Pharmaceutical Sciences. She has worked in pharmaceutical industry for more than 15 years. Her work has focused on preclinical and clinical pharmacology aspects of drug-drug interactions. Currently she is a Senior Scientist in the Clinical Pharmacology department at Genentech Inc. She has several peer reviewed papers in the area of drug interactions and also serves as a mem

Ajit Narang works for the Small Molecule Pharmaceutical Sciences Department of Genentech, Inc., in South San Francisco, CA responsible for the pharmaceutical development of new chemical entities through preclinical and early clinical stages.

He holds about two decades of pharmaceutical industry experience in the development and commercialization of oral and parenteral dosage forms and drug delivery platforms across preclinical through commercialization stages for both small and large molecule drugs. In addition to Genentech, he has worked for Bristol-Myers Squibb, Co., in New Brunswick, NJ; Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India; and Morton Grove Pharmaceuticals (currently, Wockhardt USA) in Gurnee, IL. He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutics from the Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN.

He has served as Adjunct Faculty at the Universities of Tennessee, Memphis, TN; University of Phoenix, Phoenix, AZ; University of Nebraska Medical Center, Omaha, NE; University of the Pacific, Stockton, CA; Campbell University, North Carolina; and Western Michigan University, Kalamazoo, MI. He served as Vice-Chair of the Biopharmaceutics Technical Committee (BTC) of the Pharmaceutical Quality Research Institute (PQRI) in Arlington, VA; Chair of the Formulation Design and Delivery (FDD) section of the American Association of Pharmaceutical Scientists (AAPS); and a Scientific Advisor to the Editors of JPharmSci.

Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with 54 peer-reviewed articles; 22 editorial contributions; 5 books; 10 patent applications; 47 invited talks; and 85 presentations at various scientific meetings. His current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.

In 2011, Nicolette Sammut Bartolo graduated as a pharmacist from the University of Malta. In 2012 she joined the Department of Pharmacy as a Project Assistant and worked on a RTDI funded project which was conducted in collaboration with the local pharmaceutical industry.

Dr Sammut Bartolo was awarded a distinction in Master of Science in Pharmacy degree in 2013. The research conducted for the Master degree focused on the production process of slow release pellets. In 2016, she completed a PhD with a dissertation on the development of pathways for synthetic steroids using green practices. She conducted the analyses for her PhD locally and in laboratories in Athens, Greece.

Her work was presented at numerous conferences including the Malta Medical School Conference, the APV World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology and the FIP World Congress of Pharmacy and Pharmaceutical Sciences. Dr Sammut Bartolo was a member of a Working Group within the Academic Pharmacy Section of the International Pharmaceutical Federation.

Dr Sammut Bartolo is involved in teaching related to pharmaceutical technology and green practices, in the running of laboratories, co-ordination of pharmaceutical technology related practicals and industrial visits. She also supervises a number of undergraduate and postgraduate students.

Dengfeng Dou, Executive Director of Lead Generation Unit, HitGen Inc. Dengfeng received his PhD degree in Bioorganic and Medicinal Chemistry at Wichita State University, KS, USA. He joined HitGen in 2012 and has been deeply involved in many HitGen Medicinal Chemistry projects; he has led project management department for 3 years for company portfolio management and external collaboration; he has led Lead Generation Unit, which focus on small molecule lead discovery and lead optimization using DNA encoded library technology, since 2016.

Prof. B Andallu, M.Sc in Biochemistry, Andhra University and Ph.D. from Sri Krishnadevaraya University, Anantapur, A.P. Since 1986 serving Sri Sathya Sai Institute of Higher Learning, former HOD, currently professor (Hon.), Dept. of Food and Nutritional Sciences, recipient of many awards(5) and gold medals (3), authored 5 books, LAP, Germany and contributed 12 chapters for books including Oxford Press, published>60 review and research articles, presented more than 100 research papers in National and International conferences/seminars in India and overseas, delivered guest lectures in various universities in USA (Texas Tech, Houston Clear Lake, Savana State University etc.), South Africa & Srilanka, specialized in research on ‘Natural remedies for stress-induced diseases’, guided 50 M.Sc dissertations, M.Phil and Ph.Ds,  Life member in many Scientific bodies. 

Health and well being has been man’s primary concern since time immemorial and many developing countries are thriving to achieve good health by increasing the use of plant products since they are easily available and inexpensive. Research interest has focused on various spices that possess antidiabetic, hypolipidemic, antitumor and immune stimulating properties by the presence of a wide variety of phytochemicals, viz. flavonoids, terpenoids, polyphenolics, carotenoids, saponins and phytosterols. Most of the spices, such as aniseeds (Pimpinella anisum L.), have ample traditional medicinal benefits that provide significant protection against many ailments but less exploited scientifically. Phytochemicals present in aniseeds were extracted and subjected to qualitative and quantitative tests. In vitro antioxidant activity of  the extracts was measured in terms of scavenging free radicals (ABTS, DPPH, DMPD, nitric oxide, superoxide, etc.) and reducing ferric and cupric ions, antidiabetic activity by the inhibition of carbohydrate hydrolyzing enzymes (£ amylase and glycosidase), anti-inflammatory activity in terms of inhibition of  xanthine oxidase and  lipoxidase, hypolipidemic effect by the inhibition of pancreatic lipase and HMG CoA reductase, hypotensive efficacy by means of inhibition of angiotensin converting enzyme (ACE) and anti-carcinogenic potential in terms of inhibition of growth of cancer cell lines. Aniseeds contain a number of phytochemicals, concentrated in the ethyl acetate (Ea) fraction of methanolic extract (Me) of aniseeds. Methanolic extract and ethyl acetate fraction are potent radical scavengers, anti-lipid peroxidative, antidiabetic, hypotensive, hypolipdidemic, anti-inflammatory and anticarcinogenic owing to the potential of the phytocheimcals present in aniseeds. In vivo studies in experimental diabetes patients proved aniseeds to be effective therapeutic agents in the management and alleviation of stress- induced diseases viz. diabetes.

Mrs. Vedika Dadlani has completed her M. Pharm in Medicinal Chemistry from Institute of Chemical Technology, Mumbai and is pursuing her PhD from Dr. A.P.J. Abdul Kalam Technical University, Lucknow. She has total 12 years of teaching and industrial experience. Currently she is associated with Dr. L. H. Hiranandani College of Pharmacy as an Assistant Professor and teaching Medicinal Chemistry and Pharmaceutical Analysis. Her research areas of interest are rational design of molecules with Computer aided drug design and synthesis and evaluation of novel chemotherapeutic agents including microwave synthesis for green methods of synthesis of heterocyclic molecules. She has published papers in international and national scientific journals.

The issue of emerging resistance to anti-tubercular drugs has created a formidable barrier in the effective prevention and cure of tuberculosis globally. In an attempt to identify potential new anti-mycobacterial agents, possibly comprising new pharmacophore, a novel series of 2-phenyl- 3-(5-sulfanyl-1,3,4-thiadiazol-2-yl)-1,3-thiazolidin-4-one derivatives were designed as Mycobacterium tuberculosis shikimate kinase inhibitors. The molecules were synthesized by convenient one-pot three-component reaction of amine, aldehyde and mercaptoacetic acid on montmorillonite KSF clay as a solid acidic catalyst in good yields by microwave synthesis. The structures of the newly synthesized compounds were confirmed by IR, 1H-NMR and elemental analysis and were evaluated for anti-tubercular activity by Microplate Alamar Blue Assay (MABA) against Mycobacterium tuberculosis H37Rv. Docking and ADMET studies were used to better describe the titled compounds as potential anti-tubercular agents. The compound, 2-(3,4-dimethoxyphenyl)-3-(5-sulfanyl-1,3,4-thiadiazol-2-yl)-1,3-thiazolidin-4-one (4j) was found to be the most active against Mycobacterium tuberculosis H37Rv with MIC of 1.6 μg/ml and good drug likeness and dock scores. Molecular docking study revealed that the molecules fit well into the cavity of Shikimate kinase. Also, the molecular properties and bioactivity scores for the synthesized compounds obtained by in-silico studies were found to be within the acceptable range defined for human use revealing their potential as possible drug-like compounds. The anti-tubercular activity of the titled compounds was comparable to that of the standard drug Isoniazid and Ciprofloxacin. The results indicate that the synthesized thiadiazolyl-thiazolidinone derivatives may have an affinity towards Shikimate kinase active site which can be further explored for selective target based studies. Thus these compounds could act as a potential lead for further anti-tubercular studies.

Polymeric biomaterials are one of the basis of tissue engineering. A wide range of materials has been used in medical field. Biomaterials have been used from ancient civilization of human history. With advancement of synthetic and natural biomaterials has led to the development of stimuli responsive biomaterials, known as “smart biomaterials”. Smart polymeric biomaterials are more biocompatible, biodegradable and similar to human body tissue. Smart polymer may be synthetic or naturosynthetic. Smart polymers may be temperature, light, enzyme, pH, magnetic effect, etc. sensitive and stimuli specific. These polymers have been used in development of various medical devices, artificial organs and organ parts, targeted and controlled drug delivery with effect of specificity of biomaterials. More advance and smart biomaterials will be developed with changing in present structure/s of biomaterials in future.  This talk shall be   focused on development of smart biomaterials. It discusses natural and synthetic polymers used in their preparation and most resent applications as biomaterials

She is pursing Phd from Baba Masth Nath University, Rohtak, Haryana. Since 2013 She has 8 years professional experience of teaching & research in different Institute, Industries, and University. Presently she is working as Assistance Professor in Chaudhary Bansilal Universitiy, Bhiwani, Haryana. She has published many good quality review and research article in various journals. She has guided 9 students of M. Pharm.

Oregano oil is an essential oil possessing anti-inflammatory, antioxidant, antimicrobial, and immune-boosting properties that can be used in the treatment of various skin disorders. However, its practical applications are limited due to its handling issues and poor stability in the presence of air, light, and high temperature. To overcome these problems, this study aims to entrap oregano essential oil (OEO) in ethyl cellulose (EC) microsponges to get decreased dermal toxicity and enhanced stability. The quasi emulsion solvent diffusion method was utilized for fabrication of the OEO microsponges using EC as polymer, dichloromethane (DCM) as a solvent and polyvinyl alcohol (PVA) as stabilizer. The effect of formulation variables like stirring rate, stirring time and quantity of polymer were also examined. The prepared microsponges were evaluated for particle size and production yield. Results revealed that all microformulations were in the micro size range (19.87 mm to 248.13 mm), with a good production yield (72.85%) of M6. Spherical uniform shape with a spongy structure of microsponges was confirmed by Scanning Electron Microscopy (SEM). The optimized batch of OEO microsponges was further formulated into a gel and evaluated for physical appearance, pH, spreadability, viscosity and in-vitro release. Antimicrobial activity was also performed using E. coli, which indicates that the formulated microgel is safe (on dermal cells) than pure OEO and also confirmed their increased antibacterial effect. Moreover, stability analysis indicated enhanced stability of OEO microsponge gel. Hence, this essential oil became more stable, safe along with better handling due to entrapment in microsponges leading to an efficacious carrier system.